[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

What Are Wall Street Analysts' Target Price for Vertex Pharmaceuticals Stock?

Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) develops and commercializes therapies for treating cystic fibrosis (CF). Valued at $109.2 billion by market cap, the company invests in scientific innovation to create transformative medicines for people with serious diseases. 

Shares of the biotechnology company have underperformed the broader market over the past year. VRTX has declined 3.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 25.1%. In 2026, VRTX’s stock fell 5.1%, compared to the SPX’s 8.6% rise on a YTD basis. 

Fundamentals

See More
  • Market Capitalization, $K 110,283,344
  • Shares Outstanding, K 253,805
  • Annual Sales, $ 12,001 M
  • Annual Income, $ 3,953 M
  • EBIT $ 4,681 M
  • EBITDA $ 4,891 M
  • 60-Month Beta 0.30
  • Price/Sales 9.17
  • Price/Cash Flow 24.67
  • Price/Book 5.70

Options Overview Details

View History
  • Implied Volatility 26.69% (-0.74%)
  • Historical Volatility 18.86%
  • IV Percentile 30%
  • IV Rank 19.10%
  • IV High 46.24% on 02/12/26
  • IV Low 22.08% on 08/27/25
  • Expected Move (DTE 5) 9.10 (2.09%)
  • Put/Call Vol Ratio 0.92
  • Today's Volume 1,618
  • Volume Avg (30-Day) 2,599
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 50,964
  • Open Int (30-Day) 47,115
  • Expected Range 425.43 to 443.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 34 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $4.19
  • Number of Estimates 7
  • High Estimate $4.47
  • Low Estimate $3.79
  • Prior Year $4.00
  • Growth Rate Est. (year over year) +4.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
412.27 +5.40%
on 05/05/26
456.68 -4.85%
on 05/14/26
-3.15 (-0.72%)
since 04/22/26
3-Month
412.27 +5.40%
on 05/05/26
507.92 -14.45%
on 03/10/26
-42.38 (-8.89%)
since 02/20/26
52-Week
362.50 +19.87%
on 08/11/25
507.92 -14.45%
on 03/10/26
+0.49 (+0.11%)
since 05/22/25

Most Recent Stories

More News
What Are Wall Street Analysts' Target Price for Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

$SPX : 7,473.47 (+0.37%)
JPM : 306.38 (+1.12%)
VRTX : 434.52 (+0.23%)
BBH : 184.76 (+0.39%)
Vertex to Participate in Upcoming May Investor Conferences

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and...

VRTX : 434.52 (+0.23%)
5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call

5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call

VRTX : 434.52 (+0.23%)
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

-The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany-

VRTX : 434.52 (+0.23%)
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 CY2026 Sales Expectations

Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 CY2026 Sales Expectations

VRTX : 434.52 (+0.23%)
Vertex: Q1 Earnings Snapshot

Vertex: Q1 Earnings Snapshot

VRTX : 434.52 (+0.23%)
Vertex Reports First Quarter 2026 Financial Results

– Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 – – Povetacicept program continues rapid advancement: Completed rolling...

VRTX : 434.52 (+0.23%)
Jobs Figures Roll in Friday in Canada

Monday U.S. Featured Earnings Palantir Technologies Inc. (NASDAQ: PLTR) (Q1) EPS ...

ANET : 154.03 (+3.66%)
NVO : 44.96 (+1.28%)
VRTX : 434.52 (+0.23%)
SATS : 124.20 (-3.30%)
WMB : 78.47 (+1.23%)
HSBC : 92.02 (-0.03%)
DIS : 103.00 (-0.56%)
MCD : 282.27 (-0.67%)
PAA : 24.15 (+1.98%)
UI : 610.81 (+4.18%)
AMD : 467.51 (+3.99%)
SHEL : 85.71 (-0.51%)
Vertex's Non-CF Portfolio Finally Gets Its Credibility Test Monday

Barchart Research What to Expect from VRTX Earnings VRTX Generated May 1, 2026 Current Price $423.92 EPS Estimate $$3.67 Consensus Rating Moderate Buy Average Move 6.30% Vertex's Non-CF Portfolio Finally...

VRTX : 434.52 (+0.23%)
Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect

Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect

VRTX : 434.52 (+0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 443.80
2nd Resistance Point 441.32
1st Resistance Point 437.92
Last Price 434.52
1st Support Level 432.04
2nd Support Level 429.56
3rd Support Level 426.16

See More

52-Week High 507.92
Fibonacci 61.8% 452.37
Fibonacci 50% 435.21
Last Price 434.52
Fibonacci 38.2% 418.05
52-Week Low 362.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.